In September, the FDA accepted the company's marketing application for resmetirom, granting it the agency's priority review for NASH with liver fibrosis, with a decision expected on or before Mar. 14.
Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback